Study Results from State University of Campinas (UNICAMP) Broaden Understanding of Prostate Cancer (177LU-PSMA in Metastatic Castration Resistant Prostate Cancer: Preliminary Analysis of A Brazilian Multicentric Study).
In: Drug Week, 2024-05-31, S. 897-897
serialPeriodical
Zugriff:
A recent study conducted in Brazil investigated the use of 177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study collected data from 9 Brazilian centers and included 100 male patients with a median age of 74 years. The results showed that 177Lu-PSMA therapy was effective and safe, with a mean overall survival of 12.8 months. Additionally, 65% of patients experienced a decline in PSA levels, and only 11% experienced grade 3 or 4 hematological adverse events. The study concluded that 177Lu-PSMA therapy is a promising treatment option for Brazilian patients with mCRPC. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Study Results from State University of Campinas (UNICAMP) Broaden Understanding of Prostate Cancer (177LU-PSMA in Metastatic Castration Resistant Prostate Cancer: Preliminary Analysis of A Brazilian Multicentric Study).
|
---|---|
Zeitschrift: | Drug Week, 2024-05-31, S. 897-897 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|